Expression of histone demethylase jumonji domain-containing protein 2 and estrogen receptor in bones of postmenopausal osteoporosis patients undergoing hip arthroplasty

doi:10.3969/j.issn.2095-4344.0382

Abstract

Abstract:

BACKGROUND: Histone demethylase has been shown to promote osteoblast differentiation. However, little is reported on the association between postmenopausal osteoporosis and histone demethylase and estrogen receptor.

OBJECTIVE: To study the changes in the histone demethylase jumonji domain-containing protein 2 (JMJD2) family expression in patients with postmenopausal osteoporosis, and its correlation with estrogen receptor.

METHODS: Postmenopausal patients with hip osteoarthritis undergoing total hip arthroplasty, aged 50-70 years, were enrolled, including 15 postmenopausal osteoporosis patients (experimental group) and 15 patients with no postmenopausal osteoporosis (control group). During the arthroplasty, the cancellous bone specimens from the femoral neck were collected. Then, the expression levels of JMJD2A, JMJD2B, estrogen receptor α and estrogen receptor β were detected by real-time quantitative PCR, and western blot assay.

RESULTS AND CONCLUSION: Compared with the control group, the relative expression of JMJD2A, JMJD2B, estrogen receptor α and estrogen receptor β in the experimental group were significantly decreased (P < 0.01). JMJD2A and JMJD2B were positively correlated with estrogen receptor α and estrogen receptor β (P < 0.01). These findings indicate that there is a decrease in the expression levels of JMJD2A and JMJD2B in postmenopausal osteoporosis patients. The decreased JMJD2A and JMJD2B expression is closely related to the decrease of estrogen receptor α and estrogen receptor β. Thereafter, JMJD2 may be involved in the pathogenesis of postmenopausal osteoporosis.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

Key words: Osteoporosis, Postmenopausal, Histone Demethylases, Receptors, Estrogen, Tissue Engineering

CLC Number:

R318

Guo Cheng, Tang Hong-yu, Huo Shao-chuan, Zhou Chi, Dong Lu-jue, Chen Jian-fa, Liu Yong, Wang Hai-bin. Expression of histone demethylase jumonji domain-containing protein 2 and estrogen receptor in bones of postmenopausal osteoporosis patients undergoing hip arthroplasty [J]. Chinese Journal of Tissue Engineering Research, 2018, 22(31): 4921-4925.

Figures/Tables 1

References

[1] Erdogan MO, Y?ld?z H, Artan S, et al. Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women. Osteoporos Int. 2011;22(4):1219-1225.

[2] Movérare S, Venken K, Eriksson AL, et al. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci U S A. 2003;100(23):13573-13578.

[3] Lanyon L, Armstrong V, Ong D, et al. Is estrogen receptor alpha key to controlling bones' resistance to fracture. J Endocrinol. 2004; 182(2):183-191.

[4] Lv H, Ma X, Che T, et al. Methylation of the promoter A of estrogen receptor alpha gene in hBMSC and osteoblasts and its correlation with homocysteine. Mol Cell Biochem. 2011;355(1-2): 35-45.

[5] Kawazu M, Saso K, Tong KI, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One. 2011; 6(3):e17830.

[6] Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343-357.

[7] Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static. Cell. 2002;109(7):801-806.

[8] Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7): 941-953.

[9] Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811-816.

[10] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1): 2-17.

[11] 中华医学会骨科学分会.骨关节炎诊治指南(2007 年版)[J].中华骨科杂志,2007,10(27):793-796.

[12] Wolski H, Drw?ska-Matelska N, Seremak-Mrozikiewicz A, et al. The role of Wnt/β-catenin pathway and LRP5 protein in metabolism of bone tissue and osteoporosis etiology. Ginekol Pol. 2015;86(4):311-314.

[13] Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254-262.

[14] Rivenbark AG, Strahl BD. Molecular biology. Unlocking cell fate. Science. 2007;318(5849):403-404.

[15] Tian Y, Jia Z, Wang J, et al. Global mapping of H3K4me1 and H3K4me3 reveals the chromatin state-based cell type-specific gene regulation in human Treg cells. PLoS One. 2011;6(11): e27770.

[16] 唐宏宇,郭承,董路珏,等.组蛋白去甲基化酶JMJD2 在绝经后骨质疏松症表达分析[J].中国骨质疏松杂志,2016,22(1):24-29.

[17] Labbé RM, Holowatyj A, Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am J Transl Res. 2013;6(1):1-15.

[18] Klose RJ, Yamane K, Bae Y, et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 2006;442(7100):312-316.

[19] Berry WL, Shin S, Lightfoot SA, et al. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol. 2012; 41(5):1701-1706.

[20] Kawazu M, Saso K, Tong KI, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One. 2011; 6(3):e17830.

[21] Shi L, Sun L, Li Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A. 2011; 108(18):7541-7546.

[22] Gaughan L, Stockley J, Coffey K, et al. KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res. 2013;41(14):6892-6904.